American journal of clinical dermatology · 2026
Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lau Megan, Largen Joseph, Levine Jasmine, Del Duca Ester, Mo Lillian, Tan Kathryn Jayne, Liu Daniel, Amangeldiyeva Akbobek, da Rosa Joel Correa, Edemobi Princess, Ungar Benjamin, Guttman-Yassky Emma
Аннотация
BACKGROUND: Although clinical trials have demonstrated the efficacy and safety of abrocitinib in atopic dermatitis, there remains a lack of comprehensive long-term real-world studies across diverse patient populations.
OBJECTIVE: We aimed to characterize long-term treatment responses and adverse events of abrocitinib in adults with moderate-to-severe atopic dermatitis in real-world daily practice.
METHODS: We conducted a retrospective observational study of adults with moderate-to-severe atopic dermatitis who were treated with abrocitinib between 1 January, 2022 and 1 January, 2025 at a multi-site hospital system. Final follow-up was defined as each patient's last documented clinic visit before 1 January, 2025. Primary outcomes were changes in clinical severity scores from baseline to the final follow-up. Secondary outcomes included 1-year clinical response rates, laboratory trends, adverse events, and treatment discontinuations.
RESULTS: We identified 50 adults with moderate-to-severe atopic dermatitis (mean age 40 ± 14 years; 56% female) who had been treated with abrocitinib. Most (96%) had not responded to prior systemic therapies, including dupilumab (80%) and prednisone (36%). Clinical response improved over time: at 12-24 weeks (n = 33), 43.5% achieved an improvement of 75% or more in the Eczema Area and Severity Index (EASI-75) and 42.9% achieved an Investigator's Global Assessment (IGA) 0/1; by 36-48 weeks (n = 18), these rates rose to 53.9% and 45.5%, respectively. After 1 year (n = 29), 52.6% maintained EASI-75 and 56.5% achieved IGA 0/1. Final follow-up showed significant reductions from baseline in IGA (- 48.5%), body surface area (- 60.3%), and EASI (- 58.6%) [all p < 0.0001]. Adverse events were mild, the most common were acne (8%) and nausea (6%).
CONCLUSIONS: In our real-world study, adults with moderate-to-severe atopic dermatitis treated with abrocitinib had a progressive sustained clinical improvement across various races, ages, doses, disease onsets, atopic comorbidities, and body mass index ranges.
OBJECTIVE: We aimed to characterize long-term treatment responses and adverse events of abrocitinib in adults with moderate-to-severe atopic dermatitis in real-world daily practice.
METHODS: We conducted a retrospective observational study of adults with moderate-to-severe atopic dermatitis who were treated with abrocitinib between 1 January, 2022 and 1 January, 2025 at a multi-site hospital system. Final follow-up was defined as each patient's last documented clinic visit before 1 January, 2025. Primary outcomes were changes in clinical severity scores from baseline to the final follow-up. Secondary outcomes included 1-year clinical response rates, laboratory trends, adverse events, and treatment discontinuations.
RESULTS: We identified 50 adults with moderate-to-severe atopic dermatitis (mean age 40 ± 14 years; 56% female) who had been treated with abrocitinib. Most (96%) had not responded to prior systemic therapies, including dupilumab (80%) and prednisone (36%). Clinical response improved over time: at 12-24 weeks (n = 33), 43.5% achieved an improvement of 75% or more in the Eczema Area and Severity Index (EASI-75) and 42.9% achieved an Investigator's Global Assessment (IGA) 0/1; by 36-48 weeks (n = 18), these rates rose to 53.9% and 45.5%, respectively. After 1 year (n = 29), 52.6% maintained EASI-75 and 56.5% achieved IGA 0/1. Final follow-up showed significant reductions from baseline in IGA (- 48.5%), body surface area (- 60.3%), and EASI (- 58.6%) [all p < 0.0001]. Adverse events were mild, the most common were acne (8%) and nausea (6%).
CONCLUSIONS: In our real-world study, adults with moderate-to-severe atopic dermatitis treated with abrocitinib had a progressive sustained clinical improvement across various races, ages, doses, disease onsets, atopic comorbidities, and body mass index ranges.